Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT07288216

Status	RECRUITING
Phase	Phase 2
Sponsor	Kiniksa Pharmaceuticals International, plc
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (3)

- Has well-controlled recurrent pericarditis (i.e., including having CRP \< 0.5 mg/dL within 14 days of Baseline and a pericarditis pain NRS score d 3 at Baseline)
- Has a documented history of CRP elevation (\> 1 mg/dL) associated with at least one prior acute pericarditis episode, whether the incident event or any pericarditis recurrence
- Has received treatment for RP for at least 3 months prior to Baseline with standard therapy(ies) and is currently on a stable dosing regimen including NSAIDs and/or colchicine, and/or glucocorticoids or an IL-1 pathway inhibitor (anakinra or rilonacept).

Exclusion (12)

- Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies
- Has had a pericarditis recurrence in the last 3 months prior to Baseline
- Has received an investigational drug during the 4 weeks before study drug administration or is planning to receive an investigational drug at any time during the study.
- Has a history of active or untreated, latent tuberculosis (TB) prior to screening.
- Has a history of immunodeficiency.

... and 7 more (see full listing online)

Locations (6 total)

Investigational Site 002, Santa Monica, California, United States
Investigational Site 003, New York, New York, United States
Investigational Site 005, Austin, Texas, United States
... and 3 more locations